Which hedge funds own AQST? AQUESTIVE THERAPEUTICS INC, Q2 2026 13F holders
25 tracked hedge funds disclosed a position in AQST (AQUESTIVE THERAPEUTICS INC) in their Q2 2026 13F filings, worth $68.9m in total. The largest holder by portfolio weight is Propel Bio Management, LLC at 3.1% of its book. 4 opened a new position this quarter: Gsa Capital Partners LLP, Voleon Capital Management LP, Renaissance Technologies LLC, Jain Global LLC. 7 exited: Diametric Capital, LP, Scientech Research LLC, Prelude Capital Management, LLC.
- 25
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 4
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 7
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $2.4m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $3.1m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $68.9m
- Combined value Sum of the holders' reported positions in the security.
- 2.0%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Diametric Capital, LP | 0.4% | $1.4m |
| Scientech Research LLC | 0.05% | $54.7k |
| Prelude Capital Management, LLC | 0.02% | $212k |
| ADAR1 Capital Management, LLC | 0.0% | $41.5k |
| Y-Intercept (Hong Kong) Ltd | 0.0% | $112k |
| Point72 Asset Management, L.P. | 0.0% | $1.2m |
| Millennium Management LLC | 0.0% | $107k |
Ownership over time
Who discovered AQST first? Beta
The run: Q1 2023 → Q3 2024, +337%
| Sio Capital Management, LLC | Q2 2025 | – | +0.9 pts |
| Propel Bio Management, LLC | Q1 2026 | – | 0.0 pts |
| Venrock Adviser, LLC | Q1 2024 | – | 0.0 pts |
| Stonepine Capital Management, LLC | Q1 2025 | – | −0.1 pts |
| MPM Bioimpact LLC | Q3 2024 | – | −0.4 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.